Breaking News
Get Actionable Insights with InvestingPro+: Start 7 Day FREE Trial Register here
Investing Pro 0
Ad-Free Version. Upgrade your Investing.com experience. Save up to 40% More details

Scott Matusow

  • Analysis & Opinion

Scott Matusow's Opinion & Analysis
A complete archive of Scott Matusow's articles, including current analysis & opinion.

Many Market participants are clearly not understanding the current situation in Greece and the contagion it can cause. It's not Greece alone, its the real systemic contagion risk and potential...
Identiv (NASDAQ:INVE) has been a company we have written a lot about over the last six months. Normally, we only trade small cap companies and rarely invest in them, but Identiv is one we believe is a...
Summary Cempra Pharmaceuticals expects top-line data release for community acquired bacterial pneumonia by the end of Q1'15. Cempra's Solithromycin is also designed to potentially treat a wide array...
Summary Lately, we have seen many headlines about how large companies are experiencing security breaches that have resulted in sensitive customer information being exposed to theft. Breaches where...
SUMMARY § Late last year, Identiv brought in an entirely new senior management team to turn company around. § In Q4 2013 and Q1 2014, the company’s new management took steps to...
Orexigen (NASDAQ:OREX) faces a U.S. Food and Drug Administration (FDA) approval decision for NB32 (Contrave) on September 11th, 2014.  Contrave is a combination of bupropion sustained-release (SR) and...
Summary AcelRx develops Zalviso to treat acute and breakthrough pain. We believe there is a 90% chance the company receives FDA approval on July 27. Zalviso has several advantages over intravenous...
Summary These days we hear about shareholder activism almost daily. It is next to impossible to watch CNBC and not hear discussions about some form of activism. Watch Carl Icahn, Dan Loeb, Bill...
Summary In the area of acquisitions, we’ve had a solid history of very accurate behavior-based predictions. Although many companies do an excellent job of hiding the progress of a potential...
Summary Today, we list four bio pharmaceutical companies with upcoming catalysts. Typically, under normal market conditions, their stocks normally see strong price appreciation. Just because a...